{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Primary+Disease&page=25",
    "query": {
      "condition": "Primary Disease",
      "page": 25
    },
    "page_size": 10
  },
  "pagination": {
    "page": 25,
    "page_size": 10,
    "total_count": 6315,
    "total_pages": 632,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Primary+Disease&page=26&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Primary+Disease&page=24&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-20T07:24:26.817Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01888484",
      "title": "Study of Octanorm Subcutaneous IG in Patients With PID",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Immune Deficiency Disorder"
      ],
      "interventions": [
        {
          "name": "octanorm 16.5%",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Octapharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "2 Years to 75 Years"
      },
      "enrollment_count": 75,
      "start_date": "2014-03",
      "completion_date": "2020-06-09",
      "has_results": true,
      "last_update_posted_date": "2021-08-17",
      "last_synced_at": "2026-11-20T07:24:26.817Z",
      "location_count": 7,
      "location_summary": "Birmingham, Alabama • Irvine, California • San Diego, California + 4 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Centennial",
          "state": "Colorado"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01888484"
    },
    {
      "nct_id": "NCT00004934",
      "title": "Paclitaxel and Carboplatin With or Without Epirubicin in Treating Patients With Stage IIB, Stage III, or Stage IV Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Fallopian Tube Cancer",
        "Ovarian Cancer",
        "Primary Peritoneal Cavity Cancer"
      ],
      "interventions": [
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "epirubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "conventional surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Nordic Society of Gynaecological Oncology - Clinical Trials Unit",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": null,
      "start_date": "1999-08",
      "completion_date": "2003-05",
      "has_results": false,
      "last_update_posted_date": "2013-02-04",
      "last_synced_at": "2026-11-20T07:24:26.817Z",
      "location_count": 1,
      "location_summary": "Duluth, Minnesota",
      "locations": [
        {
          "city": "Duluth",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004934"
    },
    {
      "nct_id": "NCT02269163",
      "title": "Study of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10%",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Immunodeficiency"
      ],
      "interventions": [
        {
          "name": "Immune Globulin Intravenous",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prometic's Immune Globulin Intravenous 10%",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Prometic Biotherapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "2 Years to 80 Years"
      },
      "enrollment_count": 82,
      "start_date": "2016-01-26",
      "completion_date": "2019-01-11",
      "has_results": true,
      "last_update_posted_date": "2021-11-05",
      "last_synced_at": "2026-11-20T07:24:26.817Z",
      "location_count": 13,
      "location_summary": "Irvine, California • Los Angeles, California • Centennial, Colorado + 10 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Centennial",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "North Palm Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02269163"
    },
    {
      "nct_id": "NCT07587021",
      "title": "Study of YOLT-203 in Children and Adults With Primary Hyperoxaluria Type 1 (PH1)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Hyperoxaluria Type 1",
        "PH1"
      ],
      "interventions": [
        {
          "name": "YOLT-203",
          "type": "GENETIC"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "DRUG"
      ],
      "sponsor": "YolTech Therapeutics Co., Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2026-09-16",
      "completion_date": "2028-02",
      "has_results": false,
      "last_update_posted_date": "2026-10-09",
      "last_synced_at": "2026-11-20T07:24:26.817Z",
      "location_count": 4,
      "location_summary": "Birmingham, Alabama • Aurora, Colorado • St Louis, Missouri + 1 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07587021"
    },
    {
      "nct_id": "NCT07679984",
      "title": "Evaluating the Effects of a Mindfulness Intervention on Health Outcomes in Individuals With Hypertension",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hypertension",
        "Essential (Primary) Hypertension"
      ],
      "interventions": [
        {
          "name": "Mindfulness in Motion",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Ohio State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 140,
      "start_date": "2027-03-01",
      "completion_date": "2028-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-11-12",
      "last_synced_at": "2026-11-20T07:24:26.817Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07679984"
    },
    {
      "nct_id": "NCT06730347",
      "title": "A Study of Lorigerlimab in Participants With Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Platinum-resistant Ovarian Cancer",
        "Platinum-Resistant Fallopian Tube Carcinoma",
        "Platinum-Resistant Primary Peritoneal Carcinoma",
        "Clear Cell Adenocarcinoma of Ovary",
        "Clear Cell Adenocarcinoma of Vulva",
        "Clear Cell Adenocarcinoma of Vagina",
        "Clear Cell Adenocarcinoma of Cervix",
        "Clear Cell Adenocarcinoma of Uterus",
        "Clear Cell Adenocarcinoma of Fallopian Tube",
        "Clear Cell Adenocarcinoma of Peritoneum",
        "Endometrial Cancer"
      ],
      "interventions": [
        {
          "name": "Lorigerlimab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "MacroGenics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 80,
      "start_date": "2025-05-01",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-06-02",
      "last_synced_at": "2026-11-20T07:24:26.817Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • New Orleans, Louisiana • Grand Rapids, Michigan + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06730347"
    },
    {
      "nct_id": "NCT00125164",
      "title": "Prepubertal Children With Growth Failure Associated With Primary Insulin-Like Growth Factor-1 (IGF-1) Deficiency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Growth Disorders",
        "Insulin-Like Growth Factor-1 Deficiency"
      ],
      "interventions": [
        {
          "name": "rhIGF-1 (mecasermin, Tercica, Inc.)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ipsen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "3 Years to 12 Years"
      },
      "enrollment_count": 137,
      "start_date": "2004-03",
      "completion_date": "2008-07",
      "has_results": true,
      "last_update_posted_date": "2019-09-18",
      "last_synced_at": "2026-11-20T07:24:26.817Z",
      "location_count": 1,
      "location_summary": "Brisbane, California",
      "locations": [
        {
          "city": "Brisbane",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00125164"
    },
    {
      "nct_id": "NCT04244552",
      "title": "A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Colorectal Cancer",
        "Ovarian Cancer",
        "Non-Small Cell Lung Cancer",
        "Acral Lentiginous Melanoma",
        "Head and Neck Squamous Cell Carcinoma",
        "Hepatocellular Carcinoma",
        "Esophageal Squamous Cell Carcinoma",
        "Urothelial Carcinoma",
        "DMMR Colorectal Cancer",
        "MSI-H Colorectal Cancer",
        "Melanoma",
        "Platinum-Resistant Primary Peritoneal Carcinoma",
        "Platinum-Resistant Fallopian Tube Carcinoma",
        "Platinum-Resistant Epithelial Ovarian Cancer",
        "Triple Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "ATRC-101",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pegylated liposomal doxorubicin (PLD)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Atreca, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 87,
      "start_date": "2020-02-11",
      "completion_date": "2023-11-01",
      "has_results": false,
      "last_update_posted_date": "2023-12-29",
      "last_synced_at": "2026-11-20T07:24:26.817Z",
      "location_count": 19,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Duarte, California + 15 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04244552"
    },
    {
      "nct_id": "NCT00003523",
      "title": "Aminocamptothecin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Cancer of the Peritoneum",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Primary Peritoneal Cavity Cancer"
      ],
      "interventions": [
        {
          "name": "aminocamptothecin colloidal dispersion",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gynecologic Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "13 Years and older · Female only"
      },
      "enrollment_count": null,
      "start_date": "1999-01",
      "completion_date": "2007-10",
      "has_results": false,
      "last_update_posted_date": "2013-06-21",
      "last_synced_at": "2026-11-20T07:24:26.817Z",
      "location_count": 64,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 53 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003523"
    },
    {
      "nct_id": "NCT01550315",
      "title": "Effect of Dietary Sodium Intake on Vascular Endothelium",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Postural Tachycardia Syndrome (POTS)"
      ],
      "interventions": [
        {
          "name": "Pulsitile Arterial Tonometry (PAT) Protocol",
          "type": "PROCEDURE"
        },
        {
          "name": "Calf Blood Flow in Reactive Hyperemia (CBF-RH)",
          "type": "DEVICE"
        },
        {
          "name": "Evaluation of Forearm-Mediated Dilation",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DEVICE"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 27,
      "start_date": "2012-04",
      "completion_date": "2021-09",
      "has_results": true,
      "last_update_posted_date": "2022-01-05",
      "last_synced_at": "2026-11-20T07:24:26.817Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01550315"
    }
  ]
}